BioCryst Pharmaceuticals (BCRX) Shares are Down -6.37%

BioCryst Pharmaceuticals (BCRX) has risen sharply, recording gains of 5% in the past 4 weeks. However, the stock has corrected -6.37% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 5.57% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 1.86% and the 50-Day Moving Average is 3.74%.The 200 Day SMA reached 4.25%


BioCryst Pharmaceuticals (NASDAQ:BCRX): The stock opened in the green at $4.46 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $4.5678 and a low of $4.37 for the day. The stock did not find buyers even at the lows and closed at $4.41 recording a loss of -0.90%. 807,925 shares exchanged hands during the trading day. The stock had closed at $4.41 in the previous days trading.

BioCryst Pharmaceuticals (BCRX) : The consensus price target for BioCryst Pharmaceuticals (BCRX) is $6.33 for the short term with a standard deviation of $2.88. The most optimist securities analyst among the 6 who monitor the stock believes that the stock can reach $10, however, the pessimist price target for the company is $3.

BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its products include RAPIVAB, BCX4161, BCX7353 and other second generation HAE compounds, BCX4430 and Forodesine. Peramivir is an intravenous neuraminidase inhibitor approved in multiple countries for the treatment of patients with influenza, in the United States as RAPIVAB, in Japan as RAPIACTA and in Korea as PERAMIFLU. BCX4161 is the Companys Hereditary Angioedema (HAE) product candidate. BCX7353 is a plasma kallikrein inhibitor. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.